Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Optimization and Lead Selection of Benzothiazole Amide Analogs Toward a Novel Antimycobacterial Agent.

De Groote MA, Jackson M, Gonzalez-Juarrero M, Li W, Young CL, Wong C, Graham J, Day J, Hoang T, Jarvis TC, Ribble W, Sun X, Ochsner UA.

Front Microbiol. 2018 Sep 20;9:2231. doi: 10.3389/fmicb.2018.02231. eCollection 2018.

2.

Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease.

Scriba TJ, Penn-Nicholson A, Shankar S, Hraha T, Thompson EG, Sterling D, Nemes E, Darboe F, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Johnson JL, Boom WH, Hatherill M, Valvo J, De Groote MA, Ochsner UA, Aderem A, Hanekom WA, Zak DE; other members of the ACS cohort study team.

PLoS Pathog. 2017 Nov 16;13(11):e1006687. doi: 10.1371/journal.ppat.1006687. eCollection 2017 Nov.

3.

Potential of High-Affinity, Slow Off-Rate Modified Aptamer Reagents for Mycobacterium tuberculosis Proteins as Tools for Infection Models and Diagnostic Applications.

Russell TM, Green LS, Rice T, Kruh-Garcia NA, Dobos K, De Groote MA, Hraha T, Sterling DG, Janjic N, Ochsner UA.

J Clin Microbiol. 2017 Oct;55(10):3072-3088. doi: 10.1128/JCM.00469-17. Epub 2017 Aug 9.

4.

Discovery and Validation of a Six-Marker Serum Protein Signature for the Diagnosis of Active Pulmonary Tuberculosis.

De Groote MA, Sterling DG, Hraha T, Russell TM, Green LS, Wall K, Kraemer S, Ostroff R, Janjic N, Ochsner UA.

J Clin Microbiol. 2017 Oct;55(10):3057-3071. doi: 10.1128/JCM.00467-17. Epub 2017 Aug 9.

5.

Safety, Tolerability, Systemic Exposure, and Metabolism of CRS3123, a Methionyl-tRNA Synthetase Inhibitor Developed for Treatment of Clostridium difficile, in a Phase 1 Study.

Nayak SU, Griffiss JM, Blumer J, O'Riordan MA, Gray W, McKenzie R, Jurao RA, An AT, Le M, Bell SJ, Ochsner UA, Jarvis TC, Janjic N, Zenilman JM.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e02760-16. doi: 10.1128/AAC.02760-16. Print 2017 Aug.

6.

Correction for De Groote et al., "Highly Multiplexed Proteomic Analysis of Quantiferon Supernatants To Identify Biomarkers of Latent Tuberculosis Infection".

De Groote MA, Higgins M, Hraha T, Wall K, Wilson ML, Sterling DG, Janjic N, Reves R, Ochsner UA, Belknap R.

J Clin Microbiol. 2017 May;55(5):1598. doi: 10.1128/JCM.00333-17. No abstract available.

7.

Highly Multiplexed Proteomic Analysis of Quantiferon Supernatants To Identify Biomarkers of Latent Tuberculosis Infection.

De Groote MA, Higgins M, Hraha T, Wall K, Wilson ML, Sterling DG, Janjic N, Reves R, Ochsner UA, Belknap R.

J Clin Microbiol. 2017 Feb;55(2):391-402. doi: 10.1128/JCM.01646-16. Epub 2016 Nov 16. Erratum in: J Clin Microbiol. 2017 May;55(5):1598.

8.

Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents.

Rohloff JC, Gelinas AD, Jarvis TC, Ochsner UA, Schneider DJ, Gold L, Janjic N.

Mol Ther Nucleic Acids. 2014 Oct 7;3:e201. doi: 10.1038/mtna.2014.49. Review.

9.

Specific capture and detection of Staphylococcus aureus with high-affinity modified aptamers to cell surface components.

Baumstummler A, Lehmann D, Janjic N, Ochsner UA.

Lett Appl Microbiol. 2014 Oct;59(4):422-31. doi: 10.1111/lam.12295. Epub 2014 Jul 2.

10.

Systematic selection of modified aptamer pairs for diagnostic sandwich assays.

Ochsner UA, Green LS, Gold L, Janjic N.

Biotechniques. 2014 Mar 1;56(3):125-8, 130, 132-3. doi: 10.2144/000114134. eCollection 2014.

11.

Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis.

Nahid P, Bliven-Sizemore E, Jarlsberg LG, De Groote MA, Johnson JL, Muzanyi G, Engle M, Weiner M, Janjic N, Sterling DG, Ochsner UA.

Tuberculosis (Edinb). 2014 May;94(3):187-96. doi: 10.1016/j.tube.2014.01.006. Epub 2014 Feb 7.

12.

Detection of Clostridium difficile toxins A, B and binary toxin with slow off-rate modified aptamers.

Ochsner UA, Katilius E, Janjic N.

Diagn Microbiol Infect Dis. 2013 Jul;76(3):278-85. doi: 10.1016/j.diagmicrobio.2013.03.029. Epub 2013 May 13.

PMID:
23680240
13.

Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment.

De Groote MA, Nahid P, Jarlsberg L, Johnson JL, Weiner M, Muzanyi G, Janjic N, Sterling DG, Ochsner UA.

PLoS One. 2013 Apr 18;8(4):e61002. doi: 10.1371/journal.pone.0061002. Print 2013.

14.

Development of 4H-pyridopyrimidines: a class of selective bacterial protein synthesis inhibitors.

Guiles JW, Toro A, Ochsner UA, Bullard JM.

Org Med Chem Lett. 2012 Feb 16;2(1):5. doi: 10.1186/2191-2858-2-5.

15.

Discovery and analysis of 4H-pyridopyrimidines, a class of selective bacterial protein synthesis inhibitors.

Ribble W, Hill WE, Ochsner UA, Jarvis TC, Guiles JW, Janjic N, Bullard JM.

Antimicrob Agents Chemother. 2010 Nov;54(11):4648-57. doi: 10.1128/AAC.00638-10. Epub 2010 Aug 9.

16.

Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections.

Critchley IA, Green LS, Young CL, Bullard JM, Evans RJ, Price M, Jarvis TC, Guiles JW, Janjic N, Ochsner UA.

J Antimicrob Chemother. 2009 May;63(5):954-63. doi: 10.1093/jac/dkp041. Epub 2009 Mar 3.

PMID:
19258353
17.

Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model.

Ochsner UA, Bell SJ, O'Leary AL, Hoang T, Stone KC, Young CL, Critchley IA, Janjic N.

J Antimicrob Chemother. 2009 May;63(5):964-71. doi: 10.1093/jac/dkp042. Epub 2009 Feb 26.

PMID:
19251726
18.

Inhibition of methionyl-tRNA synthetase by REP8839 and effects of resistance mutations on enzyme activity.

Green LS, Bullard JM, Ribble W, Dean F, Ayers DF, Ochsner UA, Janjic N, Jarvis TC.

Antimicrob Agents Chemother. 2009 Jan;53(1):86-94. doi: 10.1128/AAC.00275-08. Epub 2008 Nov 17.

19.

Recent advances in the preclinical evaluation of the topical antibacterial agent REP8839.

Critchley IA, Ochsner UA.

Curr Opin Chem Biol. 2008 Aug;12(4):409-17. doi: 10.1016/j.cbpa.2008.06.011. Epub 2008 Jul 11. Review.

PMID:
18620074
20.

Aminoacyl-tRNA synthetases: essential and still promising targets for new anti-infective agents.

Ochsner UA, Sun X, Jarvis T, Critchley I, Janjic N.

Expert Opin Investig Drugs. 2007 May;16(5):573-93. Review.

PMID:
17461733
21.

Transient loss of high-level mupirocin resistance in Staphylococcus aureus due to MupA polymorphism.

Driscoll DG, Young CL, Ochsner UA.

Antimicrob Agents Chemother. 2007 Jun;51(6):2247-8. Epub 2007 Apr 16.

22.

Mode of action and biochemical characterization of REP8839, a novel inhibitor of methionyl-tRNA synthetase.

Ochsner UA, Young CL, Stone KC, Dean FB, Janjic N, Critchley IA.

Antimicrob Agents Chemother. 2005 Oct;49(10):4253-62.

23.

Antibacterial activity of REP8839, a new antibiotic for topical use.

Critchley IA, Young CL, Stone KC, Ochsner UA, Guiles J, Tarasow T, Janjic N.

Antimicrob Agents Chemother. 2005 Oct;49(10):4247-52.

24.

Global analysis of cellular factors and responses involved in Pseudomonas aeruginosa resistance to arsenite.

Parvatiyar K, Alsabbagh EM, Ochsner UA, Stegemeyer MA, Smulian AG, Hwang SH, Jackson CR, McDermott TR, Hassett DJ.

J Bacteriol. 2005 Jul;187(14):4853-64.

25.

Identification of tandem duplicate regulatory small RNAs in Pseudomonas aeruginosa involved in iron homeostasis.

Wilderman PJ, Sowa NA, FitzGerald DJ, FitzGerald PC, Gottesman S, Ochsner UA, Vasil ML.

Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9792-7. Epub 2004 Jun 21.

26.

FpvB, an alternative type I ferripyoverdine receptor of Pseudomonas aeruginosa.

Ghysels B, Dieu BT, Beatson SA, Pirnay JP, Ochsner UA, Vasil ML, Cornelis P.

Microbiology. 2004 Jun;150(Pt 6):1671-80.

27.

Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets.

Hassett DJ, Cuppoletti J, Trapnell B, Lymar SV, Rowe JJ, Yoon SS, Hilliard GM, Parvatiyar K, Kamani MC, Wozniak DJ, Hwang SH, McDermott TR, Ochsner UA.

Adv Drug Deliv Rev. 2002 Dec 5;54(11):1425-43. Review.

PMID:
12458153
28.

Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis.

Yoon SS, Hennigan RF, Hilliard GM, Ochsner UA, Parvatiyar K, Kamani MC, Allen HL, DeKievit TR, Gardner PR, Schwab U, Rowe JJ, Iglewski BH, McDermott TR, Mason RP, Wozniak DJ, Hancock RE, Parsek MR, Noah TL, Boucher RC, Hassett DJ.

Dev Cell. 2002 Oct;3(4):593-603.

29.
30.

Effects of the twin-arginine translocase on secretion of virulence factors, stress response, and pathogenesis.

Ochsner UA, Snyder A, Vasil AI, Vasil ML.

Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8312-7. Epub 2002 May 28.

31.

Cloning and functional characterization of the Pseudomonas aeruginosa rhlC gene that encodes rhamnosyltransferase 2, an enzyme responsible for di-rhamnolipid biosynthesis.

Rahim R, Ochsner UA, Olvera C, Graninger M, Messner P, Lam JS, Soberón-Chávez G.

Mol Microbiol. 2001 May;40(3):708-18.

33.

Hydrogen peroxide sensitivity of catechol-2,3-dioxygenase: a cautionary note on use of xylE reporter fusions under aerobic conditions.

Hassett DJ, Ochsner UA, Groce SL, Parvatiyar K, Ma JF, Lipscomb JD.

Appl Environ Microbiol. 2000 Sep;66(9):4119-23.

34.
35.

AnkB, a periplasmic ankyrin-like protein in Pseudomonas aeruginosa, is required for optimal catalase B (KatB) activity and resistance to hydrogen peroxide.

Howell ML, Alsabbagh E, Ma JF, Ochsner UA, Klotz MG, Beveridge TJ, Blumenthal KM, Niederhoffer EC, Morris RE, Needham D, Dean GE, Wani MA, Hassett DJ.

J Bacteriol. 2000 Aug;182(16):4545-56.

36.
37.
38.

Genetics and regulation of two distinct haem-uptake systems, phu and has, in Pseudomonas aeruginosa.

Ochsner UA, Johnson Z, Vasil ML.

Microbiology. 2000 Jan;146 ( Pt 1):185-98.

PMID:
10658665
39.

Effect of catalase on hydrogen peroxide penetration into Pseudomonas aeruginosa biofilms.

Stewart PS, Roe F, Rayner J, Elkins JG, Lewandowski Z, Ochsner UA, Hassett DJ.

Appl Environ Microbiol. 2000 Feb;66(2):836-8.

40.

Quorum sensing in Pseudomonas aeruginosa controls expression of catalase and superoxide dismutase genes and mediates biofilm susceptibility to hydrogen peroxide.

Hassett DJ, Ma JF, Elkins JG, McDermott TR, Ochsner UA, West SE, Huang CT, Fredericks J, Burnett S, Stewart PS, McFeters G, Passador L, Iglewski BH.

Mol Microbiol. 1999 Dec;34(5):1082-93.

41.

The response of Pseudomonas aeruginosa to iron: genetics, biochemistry and virulence.

Vasil ML, Ochsner UA.

Mol Microbiol. 1999 Nov;34(3):399-413. Review.

42.

Bacterioferritin A modulates catalase A (KatA) activity and resistance to hydrogen peroxide in Pseudomonas aeruginosa.

Ma JF, Ochsner UA, Klotz MG, Nanayakkara VK, Howell ML, Johnson Z, Posey JE, Vasil ML, Monaco JJ, Hassett DJ.

J Bacteriol. 1999 Jun;181(12):3730-42.

43.

Pseudomonas aeruginosa fur overlaps with a gene encoding a novel outer membrane lipoprotein, OmlA.

Ochsner UA, Vasil AI, Johnson Z, Vasil ML.

J Bacteriol. 1999 Feb;181(4):1099-109.

45.

Periplasmic superoxide dismutase protects Salmonella from products of phagocyte NADPH-oxidase and nitric oxide synthase.

De Groote MA, Ochsner UA, Shiloh MU, Nathan C, McCord JM, Dinauer MC, Libby SJ, Vazquez-Torres A, Xu Y, Fang FC.

Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13997-4001.

47.

Exotoxin A production in Pseudomonas aeruginosa requires the iron-regulated pvdS gene encoding an alternative sigma factor.

Ochsner UA, Johnson Z, Lamont IL, Cunliffe HE, Vasil ML.

Mol Microbiol. 1996 Sep;21(5):1019-28.

PMID:
8885271
48.

Isolation and characterization of a Pseudomonas aeruginosa gene, ptxR, which positively regulates exotoxin A production.

Hamood AN, Colmer JA, Ochsner UA, Vasil ML.

Mol Microbiol. 1996 Jul;21(1):97-110.

PMID:
8843437
49.
50.

Production of rhamnolipid biosurfactants.

Ochsner UA, Hembach T, Fiechter A.

Adv Biochem Eng Biotechnol. 1996;53:89-118. Review.

PMID:
8578973

Supplemental Content

Loading ...
Support Center